Acta Med. 2013, 56: 33-35
https://doi.org/10.14712/18059694.2014.36
CASE 1-2013: FATAL MANIFESTATION OF MYELOPROLIFERATIVE DISEASE
References
1. G, Remacha A, Besses C, et al. Is polycythemia vera a serious disease in young adults? Haematologica 2001; 86(5): 543–4.
2. A. Annual clinical updates in hematological malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk stratification and management. Am J Hematol 2011; 86(3): 292–301.
<https://doi.org/10.1002/ajh.21946>
3. V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematol 2008; 93(3): 372–380.
<https://doi.org/10.3324/haematol.12053>
4. P, Cyprus G. Polycythemia and the heart. Texas Heart Institute Journal 1994; 21: 198–201.
5. SV, Burke RF, Lee KS, et al. Presentation of essential thrombocytosis in a 17-year-old man. Clinical Advances in Hematology & Oncology 2008; 6(2): 133–9.
6. E, Tuzun N, Sahin F, et al. Non ST-segment elevation myocardial infarction in patient with essential thrombocythemia. Thrombosis journal 2009; 7: 1.
<https://doi.org/10.1186/1477-9560-7-1>
<PubMed>
7. MW, Khan U, Greenberg BR. Cardiovascular manifestation of myeloproliferative disorders: A Review of the Literature. Hospital Physician 1999; July: 43–54.
8. A, Patel N, Burke J. Thrombocytosis and coronary occlusion. J Am Coll Cardiol Intv. 2012; 5(6): 18–19.
<https://doi.org/10.1016/j.jcin.2011.12.018>
9. AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1–12.
<https://doi.org/10.1182/blood.V64.1.1.1>
10. R, Rocca B, Patron C. Bleeding and thrombosis in myeloproliferative disorders: mechanism and treatment. Critical reviews in Oncology-Hematology 1995; 20: 203–22.
<https://doi.org/10.1016/1040-8428(94)00164-O>
11. MA, Tefferi A. Thrombosis and haemorrhage in polycythemia vera and Essentials thrombocythaemia. Br J Haematol 2004; 128: 275–290.
<https://doi.org/10.1111/j.1365-2141.2004.05277.x>
12. S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. Journal of Clinical Oncology 1990; 8: 556–562.
<https://doi.org/10.1200/JCO.1990.8.3.556>
13. R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenic mechanism and prevention. Best Pract Res Clin Haematol 2006; 19(3): 617–633.
<https://doi.org/10.1016/j.beha.2005.07.011>
